Insider · CIK 0001746738
Michael Seth Altman
Files at LYRA (Lyra Therapeutics, Inc.), NAUT (Nautilus Biotechnology, Inc.), ARYD (ARYA Sciences Acquisition Corp IV), FRNM (Perceptive Capital Solutions Corp). First filing -, latest -.
In brief
Michael Seth Altman files SEC Form 4 as director, 10% owner and CFO at LYRA (Lyra Therapeutics, Inc.), and also at NAUT (Nautilus Biotechnology, Inc.), ARYD (ARYA Sciences Acquisition Corp IV), FRNM (Perceptive Capital Solutions Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael Seth Altman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | FRNM Perceptive Capital Solutions Corp | CConversion Common Stockindirect: By Perceptive Capital Solutions Holdings | +2,066,250 | - | - | 2,352,500 | Jul 22, 2026 |
| Jul 20, 2026 | FRNM Perceptive Capital Solutions Corp | CConversion Class B Ordinary Sharesderivativeindirect: By Perceptive Capital Solutions Holdings | -2,066,250 | - | - | 0 | Jul 22, 2026 |
| Jul 31, 2024 | ARYD ARYA Sciences Acquisition Corp IV | DDisposition to issuer Class A ordinary sharesindirect: By ARYA Sciences Holdings IV | -499,000 | - | - | 0 | Jul 31, 2024 |
| Jul 31, 2024 | ARYD ARYA Sciences Acquisition Corp IV | DDisposition to issuer Class B ordinary sharesderivativeindirect: By ARYA Sciences Holdings IV | -1,000,000 | - | - | 2,647,500 | Jul 31, 2024 |
| Jul 31, 2024 | ARYD ARYA Sciences Acquisition Corp IV | DDisposition to issuer Class B ordinary sharesderivativeindirect: By ARYA Sciences Holdings IV | -2,647,500 | - | - | 0 | Jul 31, 2024 |
| Jun 14, 2024 | NAUT Nautilus Biotechnology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 17, 2024 |
| Jun 13, 2024 | LYRA Lyra Therapeutics, Inc. | AGrant or award Stock Optionderivative | +30,000 | $0.00 | $0 | 30,000 | Jun 14, 2024 |
| Jun 13, 2024 | FRNM Perceptive Capital Solutions Corp | AGrant or award Class A ordinary sharesindirect: By Perceptive Capital Solutions Holdings | +286,250 | $10.00 | $2.9M | 286,250 | Jun 13, 2024 |
Questions about Michael Seth Altman
Answered from the filings on this page, as of the latest one.
Is Michael Seth Altman buying or selling?
Michael Seth Altman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael Seth Altman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Seth Altman has 0.
Where does Michael Seth Altman file Form 4?
Michael Seth Altman has filed Form 4 at LYRA (Lyra Therapeutics, Inc.); NAUT (Nautilus Biotechnology, Inc.); ARYD (ARYA Sciences Acquisition Corp IV) as Chief Financial Officer; FRNM (Perceptive Capital Solutions Corp) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.